Does leucovorin (folinic acid) help autistic children?

Small trials hint at better talking — but the evidence is thin, mostly from one research group, and the largest trial was retracted.

Research synthesisUpdated 2026-09-245 sources includedProtocol v4.5 (Amdt. v4.6)
Talking & Communication Promising but contested
Overall Autism Signs Not enough evidence
Children With Folate Antibodies Not enough evidence

Important — please read this first. Leucovorin is a prescription medicine. In March 2026 the US FDA approved it for one rare, genetic form of cerebral folate deficiency — not for autism. Please talk with your child’s doctor before starting or stopping it. High doses can hide the blood signs of low vitamin B12 while nerve damage continues, and it must not be used in a rare condition called MTHFS deficiency.

Podcast·Two-voice deep dive

Listen to the discussion

0:00
Chapters & transcript

This is an AI-generated discussion of this article, transcribed automatically. The written summary below is the reviewed source — if the two differ, go by the summary.

0:00

What is this discussion about?

Host A Okay, let's unpack this. Imagine you are looking at one of those very early hand-drawn maps of a newly discovered island.

Host B Oh, right, like the ones with sea monsters drawn in the corners?

Host A Exactly. There are a few clearly defined coastlines, maybe a couple of marked trails where explorers have walked. But then there are these massive, intimidating blank spaces just labeled, here be dragons.

Host B I love that analogy, especially for what we're looking at today.

Host A Right, because today we are bringing you a map of a highly discussed and honestly highly debated medical intervention for autistic children. It's called oral leucovorin, which you probably know better as folinic acid.

Host B Yeah, and we are going to look really closely at what researchers have actually mapped out so far.

Host A But just to set the ground rules right up front, we are just examining the map. I mean, this deep dive is a summary of research findings, not medical advice.

Host B Right. Absolutely nothing we talk about today is a recommendation for any individual child.

Host A That is so important to say. So what exactly are we looking at for this deep dive?

Host B Well, we're looking at a very specific stack of research today. We have a Spectrum Connect findings report, a really detailed evidence audit, clinical guidance from the American Academy of Pediatrics, and, you know, a handful of trial summaries.

Host A Okay, so a pretty comprehensive stack of documents.

Host B Yeah, exactly. The goal is to figure out what the science actually says, you know, separating those marked trails from the dragons, because there is just a lot of buzz surrounding this intervention right now.

Host A Right.

1:29

What is leucovorin, and why is it being studied for autism?

Host A And to understand the map, we really have to understand the terrain first. I was reading through the AAP guidance, and it honestly blew my mind that we are talking about a basic B vitamin here.

Host B Yeah, it is literally just a form of folate.

Host A Right, but it is being dosed, monitored, and scrutinized like a heavy-hitting pharmaceutical drug. I mean, wait, so it's a vitamin, but it's being treated and monitored like a major pharmaceutical intervention?

Host B It does seem like a contradiction at first glance, for sure. But at its core, leucovorin is simply a specific reduced form of the B vitamin folate.

Host A And it's usually just taken as a pill, right?

Host B Yeah, it is typically given orally. The dosing outlined in the literature usually runs from about 0.5 to 2 milligrams per kilogram of body weight per day.

Host A Okay.

Host B And that usually maxes out at 50 milligrams a day. And, you know, it is not a new or experimental compound in the broader medical world. It actually has very well-established uses in cancer care.

Host A Oh, wow. Really? Like for chemotherapy?

Host B Exactly. It's often used to counter the toxic effects of chemotherapy, and it is also the standard treatment for a rare metabolic condition called cerebral folate deficiency, or CFD.

Host A Okay, so why are we talking about it in the context of autism? From what I gather, it's not about these kids having a poor diet or lacking folate in their blood, right?

Host B No, not at all. The theory is actually that they have low levels of folate specifically isolated in the brain.

Host A Interesting. So how does that happen?

Host B Well, the running hypothesis is that some autistic children have specific antibodies, immune system proteins, that are mistakenly attacking the body's own transport systems.

Host A Okay. And what are those called?

Host B They are called folate receptor alpha autoantibodies, or FRAA for short.

Host A FRAA, okay.

Host B Yeah, and they essentially set up a blockade of the blood-brain barrier. That prevents standard folate from crossing over into the brain tissue, where it's really needed for basic metabolic function and, like, neurotransmitter development.

Host A It sounds like a VIP pass that lets folate bypass the bouncers, the antibodies, at the brain's front door.

Host B That is exactly how it functions. Because leucovorin is a reduced form of folate, its molecular structure is just slightly different.

Host A Oh, so it doesn't even need that blocked pathway.

Host B Right. It doesn't need to use that specific blocked pathway to enter the brain. It essentially takes a side door, completely bypassing those bouncers. And that is the core biological mechanism researchers claim to be targeting here.

4:01

How many trials are there, and who ran them?

Host A Okay, so if it acts like a VIP pass, how did researchers even discover this door existed in the first place? I mean, medical research usually follows a pretty standard trajectory, right?

Host B Yeah, typically a doctor notices something in a clinic, publishes a case report, and then it builds from there.

Host A Right, and eventually if the signal is strong enough, it builds up to those gold standard randomized placebo-controlled trials.

Host B Yes, and that is the exact path leucovorin took. It started with clinical observations and single group studies.

Host A That's where a whole group gets the pill and researchers just watch what happens, right?

Host B Exactly. And eventually they secured funding for randomized placebo-controlled trials, or RCTs, to prove the VIP pass was actually working, not just, you know, a placebo effect.

Host A But here's where the map gets really messy. I was looking at the timeline of these RCTs, and there were four of them originally.

Host B Yes, four initially.

Host A But a massive one published in 2024 was flat out retracted in January of 2026 due to errors. It wasn't just corrected. It was pulled entirely.

Host B What's fascinating here is that when a major trial is retracted, you don't just lose that one paper. You lose a massive pillar supporting the entire evidence base.

Host A It shifts the center of gravity for everything we thought we knew, doesn't it?

Host B It absolutely does. So right now, we are left with just three active RCTs.

Host A And even with those three, the evidence audit threw up a massive red flag for me. The research is heavily dominated by one specific group.

Host B Right. There's a lot of overlap.

Host A Yeah. The lead trialist who conducted these major RCTs is the exact same person who authored the major 2021 systematic review that evaluated those exact same studies. I mean, is it a red flag when the person grading the homework is the exact same person who wrote it?

Host B In science, we call that a lack of independent replication. Now, it doesn't automatically mean the data is fabricated or even wrong.

Host A Right, but it's not ideal.

Host B Exactly. For a medical consensus to be sturdy, you really need a completely unconnected team of scientists, maybe in a different country with no ties to the original authors.

Host A To run the exact same experiment and get the exact same results.

Host B Precisely. When the person generating the data is the main one summarizing how good the data is, the scientific community has to view it through a highly skeptical lens.

6:23

What did the trials measure, and in how many children?

Host A Given that tight circle of researchers, we really need to look closely at what they were actually grading. What were they actually measuring in these kids?

Host B Well, the primary focus across the board was verbal communication and speech. That was the main outcome they wanted to see change.

Host A Okay, and what else did they look at?

Host B Secondary to that, they measured overall autism symptom severity using established standardized rating scales like the ADOS.

Host A Gotcha. And they looked at side effects too, right?

Host B Yes, they rigorously tracked adverse events, or side effects. And crucially, they tracked that FRAA biomarker to see if kids who actually had those bouncers responded differently than kids who didn't.

Host A Let's talk about the kids in these trials because the numbers shocked me. The three remaining RCTs had sample sizes of 48, 19, and 55 children.

Host B Yeah, it's very small.

Host A If you add that up, you are looking at a total of 122 children. I mean, that is not a sweeping population study. That is a tiny neighborhood.

Host B It is an incredibly small sample size for an intervention generating this much public buzz. And the scope of what they measured is just as narrow.

Host A Right. The evidence audit highlights massive missing pieces, doesn't it?

Host B It really does. We do not have exact study lengths captured uniformly. We have absolutely no long-term follow-up data to see if these effects last for years or just fade away.

Host A And there's zero data on outcomes for older teenagers or adults, right?

Host B Correct. The entire map is drawn based on short-term snapshots of very young children.

Host A So what does this all mean?

Host B For the actual kids in the study, were researchers just counting words spoken or were they looking at overall well-being?

8:08

Does leucovorin improve speech in autistic children?

Host A Well, that's the complex part. Let's look at the first RCT, the one with 48 children. The researchers reported a medium to large effect on verbal communication.

Host B Okay. In statistical terms, what does that mean?

Host A That's a Cohen's d of 0.70.

Host B But here is where it gets interesting. For the subgroup of children who tested positive for those FRAA antibodies, that effect size jumped to 0.91.

Host A Let's translate that for someone who doesn't speak statistics. What does a 0.91 effect size on verbal communication actually look like for a child sitting in their living room?

Host B An effect size of 0.91 is considered quite large in behavioral science. In real-world terms, it generally means a parent or clinician would clearly notice the difference without needing a chart.

Host A So we are talking about a pretty obvious shift.

Host B Yeah, it might look like a child moving from only using single words to request things to suddenly initiating a short back-and-forth exchange or using entirely new phrases spontaneously.

Host A That is a significant leap. What about the other two trials?

Host B The second RCT, which was tiny, just 19 children, measured the ADOS score, which is a gold standard observational test for autism behaviors. The children on leucovorin improved by 2.78 points. Wow.

Host A And what about the placebo group?

Host B They only had a 0.4 point improvement. And then the third RCT, with 55 children, noted a positive effect on inappropriate speech specifically.

Host A Okay. And didn't that 2021 systematic review claim some huge numbers?

Host B It did. It claimed symptom improvements ranging from 58 to 88 percent across various measures.

Host A I can completely understand why a parent reading those numbers would be rushing to their pediatrician. A nearly three-point drop on an ADOS score is huge.

Host B It really is.

Host A It could mean a child goes from severe distress during social interactions to being able to comfortably share a toy with a peer.

10:05

What are the side effects and safety risks?

Host A But we can't just talk about the sunshine.

Host B Right. We have to talk about the dragons on this map.

Host A Exactly. What were the adverse events? Because I imagine it's not all positive.

Host B If we connect this to the bigger picture, this is where we see the biological complexity of the brain. The 2021 review listed some very challenging side effects.

Host A Like what?

Host B Agitation occurred in 11.7% of participants, aggression in 9.5%, insomnia in 8.5%. That sounds rough. Anything else? There were also reports of headaches, stomach upset, and rashes.

Host A Wait, how does a simple B vitamin cause aggression and insomnia? That seems extreme.

Host B It comes down to what folate actually does once it gets inside the brain. Folate is a primary driver of methylation and neurotransmitter synthesis. It is basically the fuel for the brain's communication network.

Host A Okay, I'm following you.

Host B If a child's brain has been operating with a severe folate bottleneck, and you suddenly throw open the side door and flood the system with fuel, you are drastically revving up brain metabolism.

Host A So it can lead to overstimulation.

Host B Exactly.

Host A It sounds like tuning an old analog radio. You might twist the dial and finally lock onto a much clearer signal for speech, but by cranking up the power, you also introduce a ton of really uncomfortable high-pitched static, like the insomnia and agitation.

Host B That is a very accurate way to understand it. And the risks actually go beyond behavioral static. The clinical literature highlights two severe label-level risks with high-dose leucovorin.

Host A Okay, what's the first one?

Host B First, it can dangerously mask a vitamin B12 deficiency.

Host A Mask it how? I'm not sure I understand.

Host B Well, B12 and folate work closely together to make red blood cells. If you are deficient in B12, your blood cells look large and abnormal, which is a clear warning sign for doctors on a blood test.

Host A Okay, so the doctor sees the warning sign and treats it.

Host B Right. But if you flood the body with leucovorin, it fixes the blood cells. The blood test looks perfectly normal.

Host A Oh, wow.

Host B However, B12 is also needed to maintain the protective coating on your nerves. leucovorin does not fix that.

Host A So the nerve damage from the B12 deficiency continues silently in the background, but the doctor can no longer see the warning signs in the blood.

Host B Exactly. You could inadvertently allow irreversible nerve damage to happen just because the blood work looks fine.

Host A That is terrifying. And what was the second major risk?

Host B The second major risk is that leucovorin is strictly contraindicated for patients with a different rare genetic condition called MTHFS deficiency.

Host A Contraindicated meaning under no circumstances should they take it. What is MTHFS deficiency?

Host B It is a genetic mutation that affects how the body breaks down folate. For people with this specific deficiency, giving them this reduced form of folate causes a toxic buildup in their metabolic pathways.

Host A That doesn't sound good.

Host B It's not. It essentially jams the gears of their cellular metabolism, which can lead to severe neurological deterioration. So giving leucovorin to someone with this rare condition is incredibly dangerous.

13:22

Why is the evidence rated low to very low?

Host A Okay, so those results sound promising on the surface, but if we are dealing with a treatment that can cause aggression, mask nerve damage, and act as a toxin for certain genetic profiles, the evidence supporting its benefits better be absolutely rock solid.

Host B And unfortunately, it's not.

Host A Right, because you mentioned earlier that the evidence audit graded the certainty of this evidence as low to very low. Why so low beyond just the small sample sizes?

Host B The audit cataloged multiple design weaknesses. In several studies, blinding was inadequate.

Host A So they knew who was getting the real pill.

Host B Exactly. It means the participants, the parents, or even the researchers might have been able to figure out who was getting the active vitamin and who was getting the placebo.

Host A Which introduces massive bias.

Host B Huge bias. Furthermore, that 2021 review pooled data from observational studies that didn't even use control groups.

Host A So they were taking data from gold standard trials and mixing it in a blender with lower quality data just to inflate the numbers.

Host B Essentially, yes. And then there is the statistical problem.

Host A Right. What's wrong with the math?

Host B An editorial published by leading experts in 2026 pointed out that many of the secondary outcome improvements would not survive what statisticians call multiple comparison corrections.

Host A Let me see if I grasp this. Is this the dartboard problem?

Host B The dartboard problem.

Host A Yeah, like if I throw 50 darts at a dartboard blindfolded, pure random chance says one or two might hit the bullseye.

Host B Ah, yes.

Host A If researchers are measuring 50 different behaviors in these kids, random chance dictates that a couple of them will look like they improved even if the vitamin did nothing.

Host B That is precisely it. In rigorous science, if you throw 50 darts, you have to apply a mathematical correction to account for the fact that you took 50 chances.

Host A And the experts argue these trials did not adequately correct their math?

Host B Right. But honestly, the biggest blow to the credibility of this evidence base is that the basic addition literally does not add up.

Host A What do you mean the addition doesn't add up?

Host B That same 2026 editorial stated there were approximately 279 children studied across four trials. But the evidence audit ran the actual numbers.

Host A Okay, and what did they find?

Host B The sum of the children in the three remaining trials, 48 plus 19 plus 55, along with the 80 children from the retracted trial, only equals 202.

Host A Wait a second. So leading experts writing in 2026 are not only failing basic addition, but they are still actively citing the 2024 study that was formally retracted for errors.

Host B Yes, they are.

Host A If the math literally doesn't add up and leading experts in 2026 are still citing a retracted study, how can we trust any of this evidence?

Host B That is exactly why the evidence certainty is graded very low. When the scientific literature is this messy, when retracted data is still floating around like a ghost in expert summaries, it forces the broader scientific community to put a massive asterisk next to the word promising.

16:23

Is there a test for the folate receptor antibodies?

Host A Yeah, that lack of trust naturally leads to the massive gaps still left in the science. Let's talk about what this evidence absolutely does not answer. What are the open gaps?

Host B Well, framing these strictly as gaps in the science, we already noted the complete lack of long-term safety data and the absence of older demographics.

Host A Right, the teenagers and adults.

Host B Exactly. But the most glaring gap revolves around the FRAA biomarker itself.

Host A Right, the bouncers at the blood-brain barrier. The trial showed that the kids who tested positive for those specific antibodies had that massive 0.91 effect size. They had the best response.

Host B They did. This raises an important question, though, because according to the American Academy of Pediatrics, there is currently no FDA-cleared test for FRAA autoantibodies available for standard clinical use.

Host A Wait, really? We keep hearing that the kids with these specific antibodies get the best results. But if a pediatrician can't order a validated test for it, aren't families just flying blind?

Host B Correct. The science suggests a biological target, but medical technology has not yet provided an approved tool to actually see that target in the real world.

17:33

Is leucovorin FDA-approved for autism?

Host A So if families are flying blind, how do doctors navigate this terrain when a patient asks for a prescription? I mean, a parent walks into the clinic having read about this VIP pass on the internet and demands it.

Host B It's tough, but the clinical bodies provide a very clear framework. The AAP states plainly that there is insufficient evidence to support prescribing leucovorin for autism in the absence of cerebral folate deficiency.

Host A Meaning they do not look at the autism diagnosis alone. They treat the underlying metabolic condition if it's there.

Host B Precisely. The clinician is looking for specific neurological and physical signs of CFD.

Host A And if they suspect it?

Host B If they suspect it, they meticulously weigh the risks we discussed. They would absolutely want to check a child's B12 levels first to ensure they aren't about to mask a dangerous deficiency.

Host A Here's where it gets really interesting, though. There's a major public misunderstanding here.

Host B Oh, absolutely.

Host A In March 2026, the FDA actually did approve leucovorin, but they approved it only for one highly specific genetic form of CFD called FOLR1. Right. But because of how the Internet telephone game works, this highly targeted approval was widely and completely incorrectly reported on social media as an FDA autism approval.

Host B It is a textbook example of how complex regulatory decisions get distorted. The FDA approved a treatment for a rare genetic transport deficiency. The public translated that into a broad endorsement for an autism cure, which the FDA absolutely did not grant.

19:05

What are the key takeaways?

Host A With all this complex data, regulatory confusion, and mixed results, let's distill this down to the essentials. These are the must-knows you should mentally bookmark before you read another headline about vitamin cures.

Host B Based purely on the sources, here are the clear takeaways. Number one, a few small, fair tests show that leucovorin may improve verbal communication in some autistic children.

Host A Okay. And number two, the FDA approval from March 2026 is strictly for a rare brain folate condition, not for autism itself.

Host B Number three, the limitation. The evidence right now is currently weak. The trials are incredibly small. The field is dominated by a single research group. And one major trial was recently retracted, making the data very messy.

Host A And number four, the open question. We still do not have long-term safety data. And critically, we do not have an approved test to actually identify which children have those folate-blocking antibodies.

Host B Those are the current boundaries of the map. And because we are dealing with real biology and real children, we need to be explicitly clear as we close.

Host A Absolutely.

Host B Decisions about any individual child belong entirely in a private conversation with that child's pediatrician or care team. This deep dive cannot and does not make that call for you.

Host A Research on leucovorin continues to evolve, and Spectrum Connect will update its coverage as new, reliable evidence appears. Spectrum Connect translates autism research into plain language for parents and rigorously checks findings for accuracy against misinformation.

Host B And if you are listening and you are a credentialed expert, an MD, PhD, PsyD, or DO, and you would like to help validate our findings, please email research@spectrumconnect.us.

Host A It makes you wonder, though, doesn't it? As we look closer at the underlying biology of autism and we see how complex just one single vitamin pathway can be, how many other hidden metabolic differences are waiting to be uncovered? And are our current medical tools even precise enough to measure them yet? Or are we still just guessing at the shapes of dragons in the dark?

Key Takeaways

Small trials found some improvement in talking — three small placebo-controlled trials (48, 19 and 55 children) reported gains. In the trial of 48 children, talking improved more on leucovorin than on the dummy pill. How sure we are: low.

A fourth trial was retracted — a 2024 trial was retracted in January 2026, and we did not count it. It appears to be the trial that reported the largest effect. Without it, only one trial of 19 children speaks to overall autism signs.

Most of the evidence comes from one research group — including the main 2021 review, whose authors include that group’s lead trialist. Experts writing in 2026 said some results would not hold up once you account for how many things were measured, and that blinding was not always good enough.

The antibody question can’t be acted on yet — children with folate-blocking antibodies seemed to improve more in one trial, but there is no FDA-cleared or approved test for those antibodies.

Talk it through with your child’s doctor — if you are considering leucovorin, it is reasonable to ask whether your child has signs of cerebral folate deficiency, how progress would be checked, what dose is planned, and whether vitamin B12 should be checked first.

What this means for you

Leucovorin, also called folinic acid, is a form of the B vitamin folate. It is used in cancer care and for cerebral folate deficiency, a rare condition where folate cannot get into the brain. Some researchers think a group of autistic children have low folate in the brain, often linked to antibodies that block folate from getting in — and that leucovorin may get around that block. In a few small, fair tests (randomized, with a dummy pill), children’s talking improved on leucovorin.

Those tests are small, and most come from one research group — including the 2021 review that pooled them, which mostly drew on studies without a comparison group. A fourth trial, published in 2024, was retracted in January 2026, so we did not count it. We do not yet know whether leucovorin helps most autistic children, and we found no long-term results.

The news around this medicine has been loud. In September 2025 the US government announced it would move leucovorin toward approval. In March 2026 the FDA approved it only for one genetic form of cerebral folate deficiency, not for autism. The American Academy of Pediatrics says current evidence is insufficient to support prescribing leucovorin for autism in the absence of cerebral folate deficiency.

A few small trials hint that leucovorin may help some autistic children talk more — but the certainty is low, most of the evidence comes from one research group, and it is not approved as an autism treatment.

Who was studied. Autistic children, in trials comparing oral leucovorin with a dummy pill; one trial (55 children, from an independent research group in Iran) gave it alongside other treatment. Trials mostly measured talking and language, or autism rating scales filled in by parents or clinicians. We did not capture how long each trial lasted or each trial’s dose, and we found no results for older children or adults. Generalizability beyond this population is not established.

Where the studies landed

Promising but contested

One trial here was retracted. A 2024 randomized trial was retracted in January 2026. A 2026 expert editorial still lists it among four trials. We excluded it from every verdict on this page (tap the red mark above the covers to find it).

4 Points toward it helping

1 Mixed or inconclusive

1 Retracted — excluded

Tap the cover to open it. The review mostly pools studies without a comparison group.
One studyReview of many studies

Tap any tile to read it. The review mostly pools studies without a comparison group.

Points toward it helping4
Three small placebo-controlled trials reported benefit: better verbal communication in 48 children, better autism scores in 19, and less unusual speech in 55. A 2021 review reported “medium-to-large effect sizes” on communication — but it pooled mostly uncontrolled studies, and its authors include the lead trialist whose own trial it pools, so it is not an independent second line of evidence.
Mixed or inconclusive1
A 2026 expert editorial concluded that the “quality of evidence is still too low to recommend leucovorin as a standard intervention.” It noted that some results would not survive correction for multiple comparisons and that some studies were not adequately blinded. It still counted the now-retracted trial. No source we found pointed against benefit outright.
Retracted — excluded1
A 2024 randomized trial in the European Journal of Pediatrics was retracted in January 2026. By its size and date, it appears to be the trial of 80 children that reported the largest effect in this literature. It is excluded from every verdict here, but shown because it is still counted in at least one 2026 summary.

Spectrum Connect reviews published research on interventions parents are exploring for their autistic children — so you can see where the evidence actually stands. No agenda, no selling, no cherry-picking. Just the studies, our method, and what it means for you.

See the research behind this For anyone who wants to check our work · 5 sources
01

Where we looked

This run was a scoping search, not a full database search. We ran 2 general web searches (19 results) and 13 targeted page fetches, of which 5 could be read — several PubMed and PMC pages were blocked by bot checks, and some DOI lookups were rate-limited. That means we can’t publish per-database counts or a formal PRISMA flow for this run. Below is the search a full run executes against PubMed/MEDLINE, Embase, APA PsycINFO, Cochrane CENTRAL, Epistemonikos, trial registers, and the Retraction Watch Database and Crossref update records.

("Leucovorin"[MeSH] OR leucovorin[tiab] OR "folinic acid"[tiab] OR "calcium folinate"[tiab] OR "cerebral folate"[tiab]) AND ("Autism Spectrum Disorder"[MeSH] OR autis*[tiab] OR "ASD"[tiab]) Run on PubMed →
02

What we did with what we found

19records surfaced by 2 web searches
−3duplicates
−6promotional or secondary pages (clinic, pharmacy, blog, news, drug Q&A)
10records cited in the full record (two trials known only from an editorial share one entry)
−1retracted (Panda 2024)
−5guidance or background only, or could not be opened
5sources used for the verdicts (3 RCTs + 1 systematic review + 1 expert editorial)
03

What the strongest evidence says

Talking & communication

Three small trials (122 children) reported gains on different speech measures. In the 48-child trial, the effect on verbal communication was Cohen’s d = 0.70. Small samples, mostly one research group, and some results may not survive correction for multiple comparisons.

How sure
Low
Overall autism signs

After the retraction, one trial of 19 children remains: ADOS scores improved 2.78 points on leucovorin vs 0.4 on placebo. Too little research to judge. The same goes for children with folate-blocking antibodies, where no approved test exists.

How sure
Not enough
Side effects & safety

Usually mild but real: agitation, aggression, trouble sleeping, headaches, irritability, stomach upset and rash have been reported. Separately, the medicine’s label-level risks apply: high doses can mask low vitamin B12, and it must not be used in MTHFS deficiency.

How sure
Very Low
Ray Kawai · Protocol v4.5 BCAT · Open record
Spectrum Connect is not a medical provider, and nothing here is medical advice. This page shows where the research stands and how we got there. It is not a recommendation, and it is not a substitute for your child’s doctor or care team. What you do with it is yours to decide, together with them.

What would you like to do?

Want to talk to a parent who’s been there?

We match you with families whose kid is like yours. Free, takes two minutes.

Join Free
Heard of something we haven’t covered?Suggest an article

If another parent, a clinic or a video mentioned a therapy you can’t find here, tell us. We’ll read the research and review it next.

Suggest an article
Think we got something wrong?Report a factual error

We publish the whole record so it can be checked, and that only counts if we act on what you find. If a number looks wrong, a study is missing or has been retracted, or we’ve read a finding in a way the evidence doesn’t support, tell us.

You don’t need a research background to file one. “This doesn’t match what our doctor told us” is a useful report. Every one reaches a person: we reply within seven days, and within thirty we have either corrected the page or told you when we will. Substantive reports send the affected steps back through the protocol and need fresh sign-off before anything here changes.

Report a factual error
Are you a clinician or researcher?Review this article

If you have read this and the evidence holds up, you can sign off on it. We send you a personal review link where you confirm your credentials, and our team checks every review before anything is published. Once approved, your name and a link to your profile appear on this article.

Ask to review this